Company intelligence / Profile preview
Anixa Biosciences, Inc.
San Jose, California, United Statesanixa.com ↗
- Ownership
- Public · ANIX
- Employees
- ~5
- Development stage
- Other
01
Overview
The company has two main clinical programs: 1) An ovarian cancer CER-T therapy in Phase 1 trials with Moffitt Cancer Center showing favorable safety profile in the first two cohorts with a notable response in one patient from the first cohort; 2) A preventive breast cancer vaccine in Phase 1 trials with Cleveland Clinic targeting triple-negative breast cancer.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapy (specifically CER-T)vaccines
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Moffitt Cancer CenterCleveland Clinic
04
Financials
- Market cap
- $105.3M
- Total revenue
- $0
- Enterprise value
- $91.6M
Beyond the preview
Go deeper on Anixa Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anixa Biosciences, Inc..